(Alliance News) - Sensyne Health PLC on Wednesday said it has developed software application DBm-Health for people with or at risk of diabetes and its working with three NHS trusts for an initial UK launch.
Shares in Sensyne were up 13% at 54.00 pence in London in morning trading.
Sensyne, a clinical artificial intelligence firm based in Oxford, said the intended user population for DBm-Health will include those at risk of developing diabetes, as well as people with a diagnosis of pre-diabetes, type 1 or type 2.
The application is intended to connected diabetics to the clinician responsible for their care, granting clinicians information on a patient's status as well as whether interventions might be needed.
The product connects patients needing regular blood glucose self-monitoring to clinicians and was developed in response to the success of Sensyne's GDm-Health application for women with diabetes in pregnancy. GDm-Health has a market share of 47% across the NHS in England and is under clinical evaluation by Jefferson Health in the US.
Sensyne said it was also responding to "increasing demand from clinicians for new digital technologies and Sensyne Health products, particularly during the Covid-19 pandemic" in developing DBm-Health.
On the subject of Diabetes and Covid-19, Sensyne said: "The launch of DBm-Health comes at a time of increasing hospital admissions for acute diabetes management and emerging evidence suggesting Covid-19 may trigger the onset of diabetes in healthy people and cause poor control for existing diabetes sufferers.
"In addition, the NHS has moved rapidly to offer remote consultations, particularly for those with co-morbidities such as diabetes which puts a person at particular risk of severe Covid infection. Therefore, demand for diabetes remote monitoring has risen rapidly over the past few months and remote monitoring of diabetes is expected to remain the main method of care in the future."
The company is working with three NHS trusts to deploy DBm-Health in an initial UK launch that will "evaluate the health-economic and operational benefits of DBm-Health", with a US launch to follow near the end of its current financial year ending April 2021.
Chief Executive Paul Drayson said: "I am very proud of the speed at which the Sensyne team has responded to this clinical need and the clear demonstration of the scalability of the platform we have built at Sensyne. We are acutely aware of the concerns of diabetic patients and the people that care for them, and of the additional burden that Covid-19 has brought to the management of this complex and potentially life-threatening condition. Rapid uptake of DBm-Health in the UK has the potential to make a significant difference to diabetes care in the NHS and provides a strong foundation to launch DBm-Health in the US later this financial year."
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
